Business Context and Reporting Period
Spyre Therapeutics, Inc. (SYRE), a biopharmaceutical company focused on inflammatory bowel disease and rheumatic diseases, filed a Form 8-K on April 14, 2026. The report details a material definitive agreement entered into on April 14, 2026, regarding a public offering of common stock.
Key Financial Metrics
- Offering Size: 6,500,000 shares of common stock initially, plus a full exercise of the 30-day option for an additional 975,000 shares.
- Offering Price: $62.00 per share.
- Gross Proceeds: Approximately $463.5 million (before underwriting discounts, commissions, and offering expenses).
- Closing Date: April 16, 2026.
- Underwriters: Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C., and Guggenheim Securities, LLC.
The filing does not provide specific values for revenue, net income, operating cash flow, margins, or existing debt levels as this is a transactional report rather than a periodic financial statement.
Material Changes
The primary material change is the significant increase in liquidity resulting from the equity offering. The company raised approximately $463.5 million in gross proceeds, substantially increasing its cash position to fund operations. The filing does not provide comparative financial data to quantify changes in revenue or profitability versus prior periods.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds from the offering for the following purposes:
- Advancing programs in inflammatory bowel disease and rheumatic diseases.
- Funding preclinical studies and clinical trials.
- Supporting manufacturing and Phase 3 readiness activities for antibody programs.
- Working capital and general corporate purposes.
The offering was conducted pursuant to a shelf registration statement (Form S-3) filed on February 19, 2026, and effective on February 27, 2026.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and estimated offering expenses.
- Confirm the current cash balance and runway extension based on the $463.5 million gross inflow.
- Review the specific timeline for Phase 3 readiness activities mentioned in the use of proceeds.
- Check for any dilution impact on existing shareholders from the issuance of 7,475,000 total shares.
- Examine the Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.